Zantac was originated by GSK and launched by the ... AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in early bladder ...

Shares in GSK fell around 9% this morning after ... of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial. Judge Vivian Medinilla of Delaware Superior Court issued an ...

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in ...

Some Delaware Supreme Court justices signaled they may be skeptical of a bid by GSK Plc ... lawsuits to proceed to trial over claims that the heartburn drug Zantac is linked to cancer.

who did not know that GSK had for decades concealed an internal study that implicated the Company's liability to Zantac users; and (4) as a result, Defendants' positive statements about the ...

GSK plc (NYSE:GSK) met the main goal in a late-stage trial of linerixibat, a treatment for cholestatic pruritus, a severe itching condition caused by an autoimmune liver disease called ...

Zantac was prescribed over 15 million times annually after being introduced in the United States in 1983. The Ohio AG’s office claims that GSK and its predecessor company hit an internal study ...

In September and October 2019, GSK suspended its distribution of Zantac (the brand name for the drug ranitidine) and issued a voluntary recall after studies demonstrated that, by interacting with ...

GSK has reported positive outcomes from the randomised Phase III GLISTEN trial of the targeted inhibitor of ileal bile acid transporter (IBAT), linerixibat. The therapy aims to treat adults with ...

who did not know that GSK had for decades concealed an internal study that implicated GSK's liability to Zantac users. When the true details entered the market, the lawsuit claims that investors ...